4-Methoxyestradiol (4-Methoxy-E2) is a bioactive metabolite of estradiol, created through a methylation process facilitated by the enzyme catechol-O-methyltransferase (COMT).
Its chemical structure includes a methoxy group at the 4-position of the phenolic ring of estradiol, lending 4-Methoxy-E2 significantly different biological activities from its parent hormone, estradiol.
Unlike estradiol, it has minimal affinity for estrogen receptors and does not significantly impact steroid hormone binding globulin. This distinctive feature allows it to modulate estrogenic effects potentially reducing the risk of hormone-dependent conditions.
Moreover, 4-Methoxy-E2 exhibits notable antiangiogenic and antiproliferative properties, which are pivotal in its ability to inhibit new blood vessel formation and cell proliferation, making it a promising candidate for the treatment of various cancers and for addressing cardiovascular health concerns.
These attributes highlight 4-Methoxy-E2 as a significant compound in medical research and therapeutic applications, particularly in cancer treatment and cardiovascular disease management.
4-methoxy-E2 is a metabolite derived from estradiol, a primary bioactive form of estrogen. 4-Methoxy-E2 is formed from estradiol through a methylation process facilitated by the enzyme catechol-O-methyltransferase (COMT).
Its chemical formula is C19H26O3, featuring a methoxy group added at the 4-position of the phenolic ring of estradiol.
Unlike its parent compound estradiol, 4-methoxy-E2 has minimal binding affinity for estrogen receptors and does not significantly impact steroid hormone binding globulin. [6.]
By naturally modulating the effects of estrogen at the receptor level, 4-Methoxy-E2 helps balance hormonal activities, potentially lowering the risk of hormone-dependent conditions.
4-methoxy-E2 also exhibits potent antiangiogenic and antiproliferative properties, meaning it can inhibit the formation of new blood vessels (angiogenesis) as well as the rapid multiplication of cells (proliferation).
These effects make 4-methoxy-E2 a promising candidate for treating various cancers and other diseases associated with abnormal angiogenesis.
Several studies have investigated the potential therapeutic applications of 4-methoxy-E2 against different types of cancer, including breast cancer and lung cancer. [4., 14.] It may also have beneficial effects on cardiovascular health.
It has been shown to induce oxidative DNA damage and elevate reactive oxygen species (ROS) levels in cancer cells, contributing to its anticancer activity.
Overall, the unique pharmacological properties of 4-methoxy-E2, particularly its ability to target angiogenesis and cell proliferation, make it a compound of significant interest in cancer research and drug development.
4-methoxy-E2 (4-Methoxy-E2) is increasingly recognized for its dual capacity to influence health and contribute to disease mechanisms.
4-methoxy-E2 plays a role in cardiovascular health by inhibiting migration, proliferation, and collagen synthesis in vascular smooth muscle cells, potentially reducing the risk of vascular diseases such as atherosclerosis.
This effect is mediated via an estrogen receptor-independent mechanism, emphasizing its potential as a therapeutic agent in cardiovascular disease management.
As an estrogen metabolite, 4-methoxy-E2 (4-methoxy-E2) is involved in the complex network of hormone metabolism related to breast cancer risk. Derived from catechol estrogens through methylation by the catechol-O-methyltransferase (COMT) enzyme, 4-methoxy-E2 is considered less genotoxic than its precursors, potentially due to its reduced capacity to form reactive quinones that cause DNA damage.
It's implicated in the mitigation of oxidative damage and may have preventive effects against the oxidative metabolism of estradiol.
Additionally, it does not stimulate estrogen receptors as estradiol does, which reduces an individual’s overall estrogenic effect.
This methylation process, turning catechol estrogens into methoxyestrogens like 4-methoxy-E2, is an important detoxification pathway that may influence breast cancer risk. Furthermore, genetic variations in the COMT enzyme that impact the efficiency of this pathway could modify individual risk profiles for breast cancer.
4-methoxy-E2 (4-methoxy-E2), a metabolic product of the interaction between 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and estradiol (E2), has complex effects on human lung cells that suggest both potential benefits and risks.
In studies of human lung epithelial cells, 4-methoxy-E2 has shown to significantly inhibit cell growth and induce mitotic arrest, which could be interpreted as beneficial by potentially curbing the proliferation of cancer cells. Moreover, it increases oxidative stress markers such as reactive oxygen species (ROS) and superoxide dismutase (SOD) activity, alongside oxidative DNA damage, evidenced by the quantitative comet assay.
However, these same properties that might make 4-methoxy-E2 a candidate for anticancer therapy also hint at its potential harmful effects. The elevated oxidative stress and DNA damage could contribute to carcinogenesis if not adequately managed by cellular repair mechanisms.
The fact that antioxidant treatment did not reverse the growth inhibition caused by 4-methoxy-E2 suggests that its antiproliferative effects are robust, yet the persistence of oxidative DNA damage raises concerns about its long-term safety in therapeutic contexts.
Thus, while 4-methoxy-E2 has intriguing properties that could be leveraged in lung cancer treatment, its dual role in both inhibiting cell growth and inducing potentially harmful oxidative stress underscores the need for careful study to fully understand its mechanisms and optimize its application in a clinical setting.
Urine samples are commonly used for 4-methoxy-E2 testing.
Estrogen metabolites can be excreted in the urine, making it a reliable method for testing estrogen detoxification and comparing ratios of estrogen metabolites. Urine testing specifically assesses phase I estrogen detoxification, and it can also be used to assess phase II methylation detoxification.
Urine collection can be easier and less stressful for patients compared to blood draws, as samples can be collected at home without the need for a clinical setting.
Additionally, urinary levels can reflect longer-term hormone exposure rather than the transient levels often seen in blood, as it reflects detoxification patterns (rather than providing snapshots of levels in the bloodstream).
It is important to consult with the lab company providing testing for 4-methoxy-E2 levels. For reference, one lab provides the following reference range for urine 4-methoxy-E2 levels: [13.]
For cycling women in the luteal phase: 0.052-0.26 ng/mg creatinine/day
Hormones never act alone, and their effects are nuanced. Optimal levels of 4-methoxy-E2 in urine tests vary depending on individual health conditions, gender, and age. The 4-methoxy detoxification pathway is generally considered a preferred estrogen detoxification pathway.
One recommendation is that 60-80% of a woman's circulating estrogen utilize the 2-OH pathway; that 13-30% utilizes the 16-OH pathway; and that the remaining 7.5-11% utilize the 4-OH pathway. [12.]
Health professionals often recommend that women remain within the reference range of 0.052-0.26 ng/mg creatinine/day in urine samples.
However, a professional's recommendation will be affected by many factors including the patient’s overall health, detoxification capacity, personal and family health history, time of life, diet and lifestyle, medications, and other factors.
Regular monitoring through urinary tests is essential to ensure that the metabolite levels are within a safe range, thereby reducing the potential for DNA damage and promoting better hormonal balance and overall health.
In addition to 4-methoxy-E2, several related biomarkers play crucial roles in estrogen metabolism and hormonal balance. Understanding these biomarkers and their interactions can provide a more comprehensive assessment of hormonal health and metabolic status.
Estrone is a weaker estrogen compared to estradiol but is prevalent in postmenopausal women and can be converted back to estradiol.
Testing for estrone is important for understanding the overall estrogenic activity, especially in postmenopausal women who are at increased risk for estrogen-sensitive cancers.
Estradiol (E2), often referred to as the primary estrogen, is the precursor for 2-methoxy-E2 and other estrogen metabolites. It plays essential roles in reproductive health, bone metabolism, and cardiovascular function.
Measuring estradiol levels provides insights into overall estrogen production and ovarian function. In combination with 2-methoxy-E2, estradiol levels can help assess estrogen metabolism and balance.
Estriol is a weak estrogen predominantly produced during pregnancy. Outside of pregnancy, its levels are very low, but it has been suggested to have protective effects against breast cancer.
Testing for estriol, especially in non-pregnant states, might provide additional insights into estrogenic activity and potential protective mechanisms against estrogen-related pathologies.
Evaluating levels of 2-MeO-E2 alongside the 4-MeO-E2/4-OH-E2 ratio can provide insights into the overall methylation capacity of the body for hydroxylated estrogen metabolites. A higher ratio of 2-MeO-E2 to its precursor 2-hydroxy-E2 (2-OH-E2) has been associated with reduced breast cancer risk, suggesting efficient methylation of potentially genotoxic catechol estrogens.
Considering 2-MeO-E2 levels in the context of the 4-MeO-E2/4-OH-E2 ratio may offer a more comprehensive understanding of estrogen metabolism, methylation, and its implications for breast cancer risk.
Testing 2-OH-E2 levels in conjunction with the 4-MeO-E2/4-OH-E2 ratio can help evaluate the balance between the 2-hydroxylation and 4-hydroxylation pathways of estrogen metabolism.
A higher ratio of 2-pathway metabolites like 2-OH-E2 to 4-pathway metabolites has been associated with reduced breast cancer risk. [8.]
It is always essential to work with a qualified healthcare professional in any case of hormone imbalance. The following diet and lifestyle measures have been shown to naturally promote healthy hormone balance:
Dietary Fiber Increase: consuming more fiber helps bind estrogen in the digestive tract, promoting its excretion and reducing reabsorption. [9.]
Interestingly, one study of 240 women also showed a correlation between increased fiber intake and anovulation, possibly due to lower estrogen levels. [9.]
Cruciferous Vegetables: foods like broccoli, cauliflower, and Brussels sprouts contain indole-3-carbinol, which aids in detoxifying excessive estrogen and optimizing hormone balance. [3.]
Regular Exercise: physical activity can help balance hormones by improving metabolism and reducing fat, which is significant since body fat can produce and store estrogen. [16.]
Probiotics and Gut Health: a healthy gut flora supports proper digestion and detoxification processes, including the breakdown, elimination and balance of hormones like estrogen. [10.]
Limit Alcohol and Caffeine: reducing intake of substances that can impair liver function helps ensure the liver effectively processes and removes excess hormones. [7., 15.]
Stress Management: stress may have an impact on estrogen levels and metabolism; techniques such as yoga, meditation, or even simple breathing exercises can reduce cortisol levels and help maintain a healthy hormonal balance. [2.]
Click here to explore testing options and order testing for 4-Methoxy-E2 levels.
[1.] 4-methoxy-E2. MedChem Express. Accessed May 13, 2024. https://www.medchemexpress.com/4-methoxy-E2.html
[2.] Assad S, Khan HH, Ghazanfar H, Khan ZH, Mansoor S, Rahman MA, Khan GH, Zafar B, Tariq U, Malik SA. Role of Sex Hormone Levels and Psychological Stress in the Pathogenesis of Autoimmune Diseases. Cureus. 2017 Jun 5;9(6):e1315. doi: 10.7759/cureus.1315. PMID: 28690949; PMCID: PMC5498122.
[3.] Auborn KJ, Fan S, Rosen EM, et al. Indole-3-Carbinol Is a Negative Regulator of Estrogen. The Journal of Nutrition. 2003;133(7):2470S2475S. doi:https://doi.org/10.1093/jn/133.7.2470s
[4.] Cheng Y, Chang LW, Cheng LC, Tsai MH, Lin P. 4-methoxy-E2-induced oxidative injuries in human lung epithelial cells. Toxicology and applied pharmacology. 2007;220(3):271-277. doi:https://doi.org/10.1016/j.taap.2007.01.024
[5.] Diaz-Ruano AB, Martinez-Alarcon N, Perán M, Benabdellah K, Garcia-Martinez MLÁ, Preda O, Ramirez-Tortosa C, Gonzalez-Hernandez A, Marchal JA, Picon-Ruiz M. Estradiol and Estrone Have Different Biological Functions to Induce NF-κB-Driven Inflammation, EMT and Stemness in ER+ Cancer Cells. Int J Mol Sci. 2023 Jan 7;24(2):1221. doi: 10.3390/ijms24021221. PMID: 36674737; PMCID: PMC9865376.
[6.] Dubey RK, Tofovic SP, Jackson EK. Cardiovascular Pharmacology of Estradiol Metabolites. Journal of Pharmacology and Experimental Therapeutics. 2003;308(2):403-409. doi:https://doi.org/10.1124/jpet.103.058057
[7.] Emanuele MA, Wezeman F, Emanuele NV. Alcohol's effects on female reproductive function. Alcohol Res Health. 2002;26(4):274-81. PMID: 12875037; PMCID: PMC6676690.
[8.] Falk, R.T., Brinton, L.A., Dorgan, J.F. et al. Relationship of serum estrogens and estrogen metabolites to postmenopausal breast cancer risk: a nested case-control study. Breast Cancer Res 15, R34 (2013). https://doi.org/10.1186/bcr3416
[9.] Gaskins AJ, Mumford SL, Zhang C, et al. Effect of daily fiber intake on reproductive function: the BioCycle Study. The American Journal of Clinical Nutrition. 2009;90(4):1061-1069. doi:https://doi.org/10.3945/ajcn.2009.27990
[10.] Maeng LY, Beumer A. Never fear, the gut bacteria are here: Estrogen and gut microbiome-brain axis interactions in fear extinction. International Journal of Psychophysiology. 2023;189:66-75. doi:https://doi.org/10.1016/j.ijpsycho.2023.05.350
[11.] PubChem. 4-methoxy-E2. pubchem.ncbi.nlm.nih.gov. Accessed May 13, 2024. https://pubchem.ncbi.nlm.nih.gov/compound/4-methoxy-E2
[12.] RUPA DUTCH Complete M+F Sample Report.pdf. Google Docs. Accessed April 27, 2024. https://drive.google.com/file/d/1-qmxwjo6B2TVYlgCS-FlcyF8FuqRdZEe/view
[13.] RUPA Health. 1.Estrogen Metabolites Profile Sample Report.pdf. Google Docs. Accessed May 1, 2024. https://drive.google.com/file/d/1nEwGz74OzsPUDQTwjEnyAkWf-Zo3JZ_0/view
[14.] Samavat H, Kurzer MS. Estrogen metabolism and breast cancer. Cancer Lett. 2015 Jan 28;356(2 Pt A):231-43. doi: 10.1016/j.canlet.2014.04.018. Epub 2014 Apr 28. PMID: 24784887; PMCID: PMC4505810.
[15.] Sisti JS, Hankinson SE, Caporaso NE, Gu F, Tamimi RM, Rosner B, Xu X, Ziegler R, Eliassen AH. Caffeine, coffee, and tea intake and urinary estrogens and estrogen metabolites in premenopausal women. Cancer Epidemiol Biomarkers Prev. 2015 Aug;24(8):1174-83. doi: 10.1158/1055-9965.EPI-15-0246. Epub 2015 Jun 10. PMID: 26063478; PMCID: PMC4526325.
[16.] Smith AJ, Phipps WR, Thomas W, Schmitz KH, Kurzer MS. The effects of aerobic exercise on estrogen metabolism in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):756-64. doi: 10.1158/1055-9965.EPI-12-1325. PMID: 23652373; PMCID: PMC3648856.